Trials / Completed
CompletedNCT00192712
Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | irinotecan, gemcitabine |
Timeline
- Start date
- 2002-11-01
- Completion
- 2010-09-01
- First posted
- 2005-09-19
- Last updated
- 2010-11-10
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00192712. Inclusion in this directory is not an endorsement.